Bionik Laboratories Launches Rental Financing Option for Healthcare Institutions
Company provides rental program to enhance commercialization
TORONTO and BOSTON, March 21, 2017 (GLOBE NEWSWIRE) -- Bionik Laboratories Corp. (OTCQX:BNKL) (“Bionik” or the "Company"), a global pioneering robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological disorders, announced today that it’s partnering with a financing partner in order to offer a product rental program to make robotic rehabilitation products more affordable to health care institutions.
The Company in its commercialization process has determined that financing of Bionik Robotic Devices is an important option to provide to hospitals and other healthcare facilities. Bionik has now executed an agreement with a US Based finance partner that allows the Company to provide its products to hospitals and clinics on a rental basis within the United States. The program will assist healthcare providers in managing their costs, while allowing Bionik to provide offerings to a much larger customer base.
“Management is extremely pleased to launch this rental program,” stated Mr. Peter Bloch, Chief Executive Officer and Chairman of the Board. “I firmly believe that this is an important step for us as an emerging medical device and robotics company. This program assists our customers with their budget constraints. We believe that this type of innovative financing for healthcare providers will allow robotic technologies to become more affordable to our healthcare provider partners and more accessible to those patients in need of assistance.”
About Bionik Laboratories
Bionik Laboratories (OTCQX:BNKL), is a global, pioneering robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological disorders. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility impaired patients, including three products on the market and four products in varying stages of development. The InMotion Systems - the InMotion ARM™, InMotion Wrist™, InMotion Hand™ and InMotion AnkleBot™, are designed to provide intelligent, patient-adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery. Bionik is also developing a lower-body exoskeleton, ARKE™, designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking. ARKE is expected to be designed to continually adapt to a patient’s ability and provide real time feedback to the physiotherapist.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other robotic rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
Contact: Investor Relations Bionik Laboratories email@example.com (800) 906-6498
Released March 21, 2017